Fjarde AP Fonden, the Fourth Swedish National Pension Fund, has increased its investment in HCA Healthcare, Inc. by 13.9%, bringing its total stake to approximately $19.51 million. This change was revealed in the most recent 13F filing with the U.S. Securities and Exchange Commission (SEC), which showed that the fund now holds 45,769 shares after acquiring an additional 5,600 shares in the third quarter.
The investment landscape surrounding HCA Healthcare, listed on the New York Stock Exchange under the symbol HCA, has seen significant activity as other institutional investors also adjusted their positions. Notably, Park Place Capital Corp raised its stake by an impressive 2,336%, now holding 1,218 shares valued at $474,000 after adding 1,168 shares in the previous quarter. Similarly, Cerity Partners LLC increased its holdings by 13.1%, owning 43,920 shares worth $18.72 million after buying an additional 5,092 shares.
Swiss National Bank also enhanced its investment, raising its stake by 4.3% in the second quarter and owning 558,900 shares valued at $214.12 million. Other notable moves include Cherokee Insurance Co, which acquired a new stake worth approximately $3.87 million, and Harrell Investment Partners LLC, which boosted its position by 176.3%, now owning 1,815 shares valued at $695,000. Currently, hedge funds and institutional investors control approximately 62.73% of HCA’s stock.
Analysts Boost Price Targets for HCA Healthcare
In light of these developments, several analysts have revised their price targets for HCA shares. Wall Street Zen upgraded its rating from “buy” to “strong-buy” on October 25, 2023. KeyCorp increased its price objective from $465.00 to $475.00, maintaining an “overweight” rating. TD Cowen also raised its target from $380.00 to $490.00, while Cantor Fitzgerald reaffirmed an “overweight” rating.
According to data from MarketBeat, HCA Healthcare currently holds a consensus rating of “Moderate Buy,” with an average target price of $487.00. The stock has attracted attention with 15 analysts rating it as a Buy, nine as Hold, and one as Sell.
Recent positive sentiment surrounding HCA Healthcare includes a report from Leerink Partners, which raised its price target to $507.00 while maintaining an “outperform” rating, indicating strong confidence in the company’s earnings growth. Furthermore, HCA plans to expand its operations significantly in Florida, aiming to operate 81 freestanding emergency departments by the end of the first quarter. This expansion is expected to enhance outpatient capacity and drive higher-margin volumes.
Financial Performance and Future Outlook
HCA Healthcare’s recent financial performance has been robust. The company reported earnings per share (EPS) of $6.96 for the quarter ending October 24, 2023, surpassing analysts’ expectations of $5.64 by $1.32. Revenue reached $19.16 billion, exceeding predictions of $18.55 billion, reflecting a year-over-year revenue increase of 9.6%.
Looking ahead, HCA Healthcare has projected EPS guidance for fiscal year 2025 between $27.00 and $28.00. Analysts anticipate the company will deliver an EPS of $24.98 for the current year.
In addition to its financial achievements, HCA recently announced a quarterly dividend of $0.72, which was paid out on December 29, 2023, to shareholders on record as of December 15, 2023. This dividend represents an annualized yield of 0.6% and a payout ratio of 11.13%.
In manager-level changes, HCA appointed Erica Rossitto as chief nurse executive, effective February 1, 2024, to strengthen nursing leadership across its extensive network of over 100,000 nurses.
As HCA Healthcare continues to expand its reach and enhance its operational capabilities, the ongoing investments and positive analyst ratings suggest a confident outlook for the company in the competitive healthcare market.
